Protagonist Therapeutics (PTGX) Misses Q2 EPS by 3c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.68), $0.03 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Wynn Resorts prices $900M senior notes offering at 6.875%
• Redwood Trust prices $185M convertible notes due 2030